Neuraxpharm has struck a deal to acquire Buccolam (midazolam), “the only buccal midazolam approved across Europe,” from Takeda in a move that the central nervous system specialist says will strengthen its position in several European countries while also offering the opportunity to expand its footprint into markets such as the Nordics and Ireland.
Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
More from Deals
Fresenius Kabi is to diversify its offering beyond immunology and oncology after putting pen to paper on a deal for a US biosimilar to Eylea, in the wake of Amgen’s surprise at-risk launch.
2024 was truly a dealmaking year for Bio-Thera, with the latest partnership expanding the net for its ustekinumab biosimilar.
Chinese biosimilars developer Bio-Thera is expanding its Latin American partnership with SteinCares with the addition of a third product.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
More from Business
In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.
In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.
GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.